OM · Outset Medical, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.86M | - | $29.43M | $31.42M | $29.75M | - | $28.67M | $27.39M | $28.17M | - |
| Cost of Revenue | $15.77M | - | $17.84M | $19.55M | $18.69M | - | $18.85M | $17.61M | $19.95M | - |
| Gross Profit | $12.10M | - | $11.59M | $11.87M | $11.07M | - | $9.82M | $9.78M | $8.21M | - |
| R&D | $5.62M | - | $5.38M | $5.29M | $5.51M | - | $8.14M | $9.73M | $12.63M | - |
| SG&A | $10.12M | - | $8.48M | $9.16M | $8.30M | - | $10.10M | $12.68M | $11.44M | - |
| Total Operating Expenses | $29.01M | - | $27.40M | $28.73M | $27.46M | - | $33.66M | $40.55M | $45.13M | - |
| D&A | $795.0K | - | - | - | $1.29M | - | - | - | $1.46M | - |
| Operating Income | ($16.92M) | - | ($15.81M) | ($16.86M) | ($16.40M) | - | ($23.84M) | ($30.76M) | ($36.91M) | - |
| Interest Expense | $3.37M | - | $3.48M | $3.48M | $3.56M | - | $6.07M | $6.01M | $5.97M | - |
| Income Tax | $217.0K | - | $404.0K | $104.0K | $115.0K | - | $182.0K | $151.0K | $162.0K | - |
| Net Income | ($18.98M) | - | ($17.84M) | ($18.54M) | ($25.78M) | - | ($27.94M) | ($34.45M) | ($39.94M) | - |
| EPS - Basic | ($1.03) | - | ($1.00) | ($1.04) | ($3.66) | - | ($8.25) | ($9.90) | ($11.70) | - |
| EPS - Diluted | ($1.03) | - | ($1.00) | ($1.04) | ($3.66) | - | ($8.25) | ($9.90) | ($11.70) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.56M | $35.01M | $36.44M | $39.56M | $75.93M | $124.01M | $33.29M | $37.86M | $32.18M | $68.51M |
| Accounts Receivable | $25.32M | $28.33M | $32.96M | $34.89M | $36.89M | $35.62M | $34.26M | $34.12M | $36.48M | $32.98M |
| Inventory | $49.65M | $47.61M | $49.29M | $52.25M | $55.77M | $59.39M | $61.44M | $61.60M | $55.84M | $49.22M |
| Accounts Payable | $1.44M | $554.0K | $1.72M | $1.45M | $1.17M | $3.86M | $4.29M | $5.25M | $6.77M | $5.83M |
| Current Assets | $236.71M | $250.88M | $265.37M | $275.58M | $286.56M | $258.22M | $275.27M | $295.14M | $325.39M | $291.22M |
| Total Assets | $249.45M | $264.50M | $277.25M | $288.80M | $301.21M | $275.80M | $292.89M | $314.53M | $346.24M | $313.80M |
| Current Liabilities | $37.61M | $37.63M | $37.45M | $36.91M | $34.22M | $45.38M | $42.43M | $43.43M | $50.67M | $55.32M |
| Long-term Debt | $96.94M | $96.24M | $95.52M | $94.81M | $94.11M | $197.38M | $197.18M | $196.99M | $196.81M | $130.11M |
| Total Liabilities | $137.77M | $137.54M | $134.89M | $134.02M | $131.34M | $248.98M | $245.07M | $245.94M | $253.04M | $190.91M |
| Stockholders' Equity | $111.69M | $126.95M | $142.37M | $154.78M | $169.87M | $26.82M | $47.82M | $68.60M | $93.20M | $122.89M |
| Retained Earnings | ($1.19B) | ($1.17B) | ($1.15B) | ($1.13B) | ($1.12B) | ($1.09B) | ($1.06B) | ($1.04B) | ($1.00B) | ($961.75M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($12.84M) | - | - | - | ($25.66M) | - | - | - | ($45.91M) | - |
| Investing Cash Flow | $7.90M | - | - | - | ($78.08M) | - | - | - | ($59.03M) | - |
| Financing Cash Flow | $501.0K | - | - | - | $55.66M | - | - | - | $68.61M | - |
| CapEx | $65.0K | - | - | - | $123.0K | - | - | - | $354.0K | - |
| Free Cash Flow | ($12.91M) | - | - | - | ($25.79M) | - | - | - | ($46.27M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 43.4% | - | 39.4% | 37.8% | 37.2% | - | 34.3% | 35.7% | 29.2% | - |
| Operating margin | -60.7% | - | -53.7% | -53.7% | -55.1% | - | -83.2% | -112.3% | -131.0% | - |
| EBITDA margin | -57.9% | - | - | - | -50.8% | - | - | - | -125.9% | - |
| Net margin | -68.1% | - | -60.6% | -59.0% | -86.7% | - | -97.5% | -125.8% | -141.8% | - |
| Free cash flow margin | -46.3% | - | - | - | -86.7% | - | - | - | -164.3% | - |
| FCF / Net income | 0.68 | - | - | - | 1.00 | - | - | - | 1.16 | - |
| R&D / Revenue | 20.2% | - | 18.3% | 16.8% | 18.5% | - | 28.4% | 35.5% | 44.9% | - |
| SG&A / Revenue | 36.3% | - | 28.8% | 29.2% | 27.9% | - | 35.2% | 46.3% | 40.6% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.6% | - | -6.4% | -6.4% | -8.6% | - | -9.5% | -11.0% | -11.5% | - |
| Return on equity | -17.0% | - | -12.5% | -12.0% | -15.2% | - | -58.4% | -50.2% | -42.9% | - |
| Return on invested capital | -6.4% | - | -5.3% | -5.3% | -4.9% | - | -7.7% | -9.2% | -10.1% | - |
| Liquidity | ||||||||||
| Current ratio | 6.29 | 6.67 | 7.09 | 7.47 | 8.37 | 5.69 | 6.49 | 6.80 | 6.42 | 5.26 |
| Quick ratio | 4.97 | 5.40 | 5.77 | 6.05 | 6.74 | 4.38 | 5.04 | 5.38 | 5.32 | 4.37 |
| Cash ratio | 0.81 | 0.93 | 0.97 | 1.07 | 2.22 | 2.73 | 0.78 | 0.87 | 0.64 | 1.24 |
| Leverage | ||||||||||
| Debt / Equity | 0.87 | 0.76 | 0.67 | 0.61 | 0.55 | 7.36 | 4.12 | 2.87 | 2.11 | 1.06 |
| Debt / Assets | 0.39 | 0.36 | 0.34 | 0.33 | 0.31 | 0.72 | 0.67 | 0.63 | 0.57 | 0.41 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -5.0x | - | -4.5x | -4.9x | -4.6x | - | -3.9x | -5.1x | -6.2x | - |
| Equity multiplier | 2.23 | 2.08 | 1.95 | 1.87 | 1.77 | 10.28 | 6.12 | 4.59 | 3.72 | 2.55 |
| Liabilities / Assets | 0.55 | 0.52 | 0.49 | 0.46 | 0.44 | 0.90 | 0.84 | 0.78 | 0.73 | 0.61 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | - | 0.11 | 0.11 | 0.10 | - | 0.10 | 0.09 | 0.08 | - |
| Inventory turnover | 0.32 | - | 0.36 | 0.37 | 0.34 | - | 0.31 | 0.29 | 0.36 | - |
| Days sales outstanding | 332d | - | 409d | 405d | 453d | - | 436d | 455d | 473d | - |
| Days inventory outstanding | 1149d | - | 1008d | 975d | 1089d | - | 1190d | 1277d | 1021d | - |
| Days payable outstanding | 33d | - | 35d | 27d | 23d | - | 83d | 109d | 124d | - |
| Cash conversion cycle | 1448d | - | 1382d | 1354d | 1519d | - | 1543d | 1623d | 1370d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.0x | - | 0.0x | 0.0x | 0.0x | - | 0.0x | 0.0x | 0.0x | - |
| P / S | 0.0x | - | 0.0x | 0.0x | 0.0x | - | 0.0x | 0.1x | 0.1x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -6.3% | - | 2.7% | 14.7% | 5.6% | - | -5.6% | -24.0% | -15.8% | - |
| Revenue CAGR (3y) | -5.9% | - | 2.0% | 7.8% | -0.9% | - | 2.9% | 2.8% | 7.1% | - |
| Revenue CAGR (5y) | 4.0% | - | 62.1% | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 9.3% | - | 18.0% | 21.3% | 34.7% | - | 37.2% | 27.0% | 27.8% | - |
| Operating income growth (YoY) | -3.2% | - | 33.7% | 45.2% | 55.6% | - | 47.6% | 29.2% | 15.1% | - |
| Net income growth (YoY) | 26.4% | - | 36.2% | 46.2% | 35.5% | - | 39.5% | 21.8% | 9.2% | - |
| EPS growth (YoY) | 71.9% | - | 87.9% | 89.5% | 68.7% | - | -787.1% | -1000.0% | -1200.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 49.9% | - | - | - | 44.3% | - | - | - | -1.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -34.3% | 373.4% | 197.7% | 125.6% | 82.3% | -78.2% | -68.6% | -62.5% | -56.9% | -50.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$204.28M totalProduct$84.81M · 41.5%
Consumables Product$54.08M · 26.5%
Service And Other Revenue$34.67M · 17.0%
Consoles Product$30.73M · 15.0%
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing Outset Medical against the 5 most active filers in the same SIC group.